Search

Zai Lab Ltd ADR

Закрыт

СекторЗдравоохранение

26 10.4

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

23.49

Макс.

26.63

Ключевые показатели

By Trading Economics

Доход

-607K

-51M

Продажи

-28M

100M

Прибыль на акцию

-0.46

Рентабельность продаж

-51.215

Сотрудники

1,784

EBITDA

4.1M

-44M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+38.52% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-331M

2.1B

Предыдущая цена открытия

15.6

Предыдущая цена закрытия

26

Новостные настроения

By Acuity

50%

50%

128 / 340 Рейтинг в Healthcare

Zai Lab Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 авг. 2026 г., 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

10 авг. 2026 г., 23:52 UTC

Event
News
Social Media

Plug Power shares are higher in after-market trading following strong second-quarter results that exceeded analyst expectations and an improved revenue growth outlook.

10 авг. 2026 г., 23:51 UTC

News

First Horizon Corp shares rise in after-market hours following James Petrillo's appointment as Vice President, De Novo New Build Leader to enhance banking centers.

10 авг. 2026 г., 23:51 UTC

News
Social Media

Riot Platforms reported Q2 revenue of $174.2 million, exceeding expectations. Shares rose sharply in after-hours trading following a major data center lease announcement.

10 авг. 2026 г., 23:51 UTC

News
Social Media

FutureFuel Corp reported second-quarter revenues of $78.7 million, a 120.6% increase year-over-year. Shares are trading higher in after-market hours following the results.

10 авг. 2026 г., 23:51 UTC

Event
News
Social Media

Upwork Inc. shares fell sharply in after-market hours following disappointing second-quarter results and lowered full-year revenue guidance of $730 million to $750 million.

10 авг. 2026 г., 23:46 UTC

News

Fortuna Silver Mines acquires the Bambadji Project for $200 million, boosting growth potential in West Africa. Shares are higher in after-market trading.

10 авг. 2026 г., 23:42 UTC

News

AT&T Inc. filed a $1.1 billion term sheet for floating rate notes due in 2028, contributing to lower shares in after-market trading.

10 авг. 2026 г., 23:41 UTC

News

Kyndryl Holdings plans to acquire Healthcare IT Leaders to enhance its healthcare capabilities. Shares are trading higher in after-market hours following the announcement.

10 авг. 2026 г., 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

10 авг. 2026 г., 23:41 UTC

News

Enphase Energy shares are lower in after-market trading following governance enhancements announced by the board after its 2026 Annual Meeting vote.

10 авг. 2026 г., 23:41 UTC

News

Toast Inc. shares are trading lower in after-market hours following Elena Gomez's sale of 17,076 shares, reducing her ownership by 9%.

10 авг. 2026 г., 23:41 UTC

News

Harrow Inc shares declined in after-market hours following a second-quarter EPS miss of -$0.46, despite revenue of $70.66 million exceeding expectations.

10 авг. 2026 г., 23:41 UTC

News

Hf Foods Group Inc reported strong Q2 results, with revenue of $323.8 million and GAAP net income of $2.6 million, driving shares higher in after-market hours.

10 авг. 2026 г., 23:41 UTC

News

Curtiss-Wright Corp raised its share repurchase program to $160 million, boosting investor sentiment as shares gained during after-market hours.

10 авг. 2026 г., 23:41 UTC

News
Social Media

Hims & Hers Health reported a net loss of $86.3 million in Q2, contributing to a decline in share price during after-market trading.

10 авг. 2026 г., 23:41 UTC

News

Rapid7 shares rise in after-hours trading following second-quarter results that exceeded expectations and positive third-quarter guidance.

10 авг. 2026 г., 23:41 UTC

Event
News

Alcon AG reported second-quarter adjusted EPS of $0.84, surpassing estimates. The company raised its fiscal 2026 EPS guidance, boosting shares in after-market hours.

10 авг. 2026 г., 23:41 UTC

News
Social Media

Entravision Communications shares fell sharply after reporting mixed Q2 results, with earnings of $0.19 and revenues of $227.9 million amid declining broadcast advertising revenue.

10 авг. 2026 г., 23:41 UTC

News

Celsius Holdings Inc. shares are lower in after-market trading following significant leadership changes, including the departure of President Eric Hanson.

10 авг. 2026 г., 23:36 UTC

News

Purple Innovation shares fell after the company reported Q2 2026 earnings of -$0.74, missing estimates, and reduced full-year revenue guidance to $420 million to $440 million.

10 авг. 2026 г., 23:36 UTC

Correlated Moves
News

Pomerantz LLP has filed a class action lawsuit against Zillow Group Inc, contributing to a decline in shares during after-market trading.

10 авг. 2026 г., 23:36 UTC

News

Valero Energy shares are higher in after-market trading, reflecting a five-year average annual return of 36.59%, turning a $100 investment into $468.33.

10 авг. 2026 г., 23:36 UTC

News

Phillips Edison & Co Inc shares are lower in after-market hours following a $400 million stock sale announcement, raising concerns over potential dilution.

10 авг. 2026 г., 23:31 UTC

News

Tactile Systems Technology shares fell in after-market hours following a revenue guidance cut, despite a rise in net income and adjusted EBITDA surpassing expectations.

10 авг. 2026 г., 23:31 UTC

News

L3Harris Technologies completed a successful hot-fire test for the Next Generation Interceptor program, boosting shares in after-market trading.

10 авг. 2026 г., 23:31 UTC

News

Definitive Healthcare reported Q2 adjusted EPS of $0.05, exceeding estimates. The stock rose sharply during after-market hours amid positive guidance and CEO comments.

10 авг. 2026 г., 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

10 авг. 2026 г., 23:26 UTC

News

RadNet Inc reported record Q2 revenue and adjusted EBITDA. Shares are trading higher in after-market hours, reflecting positive investor sentiment following the earnings report.

10 авг. 2026 г., 23:21 UTC

News
Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

Сравнение c конкурентами

Изменение цены

Zai Lab Ltd ADR Прогноз

Целевая цена

By TipRanks

38.52% рост

Прогноз на 12 месяцев

Средняя 32.65 USD  38.52%

Максимум 45 USD

Минимум 21.6 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Zai Lab Ltd ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

3

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

128 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat